|
|
Vaccine Detail
|
NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007094
- Type: Dendritic cell vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: NY-ESO-1
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Lopes et al., 2006)
- Detailed Gene Information: Click Here.
- CTAG1B
gene engineering:
- Type: Recombinant protein preparation
- Description: (Lopes et al., 2006)
- Detailed Gene Information: Click Here.
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description: (Lopes et al., 2006)
- Detailed Gene Information: Click Here.
- Tyrosinase
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description: (Lopes et al., 2006)
- Detailed Gene Information: Click Here.
- Preparation: DCs are transduced by a lentiviral vector encoding the tumor antigen genes (Lopes et al., 2006).
- Description: This is for Melanoma Cancer (NCT00313508). A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL)- and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival (Lopes et al., 2006; NCIT_C114380).
|
| Host Response |
|
|
| References |
Lopes et al., 2006: Lopes L, Fletcher K, Ikeda Y, Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer immunology, immunotherapy : CII. 2006; 55(8); 1011-1016. [PubMed: 16311731].
NCIT_C114380: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114380]
NCT00313508: [https://clinicaltrials.gov/ct2/show/NCT00313508]
|
|
